PLEU16099 / AAML1531 / Angela GirvinResearch Question:
Does treating a person's cancer based on how they respond to the first course of treatment
be effective while reducing the side effects in patients with Down syndrome?
Basic Study Information
Purpose:Location: University of Rochester
This phase III trial studies response-based chemotherapy in treating newly diagnosed
acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome.
Drugs used in chemotherapy work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Response-based chemotherapy separates patients into different risk groups
and treats them according to how they respond to the first course of treatment (Induction
I). Response-based treatment may be effective in treating acute myeloid leukemia or
myelodysplastic syndrome in younger patients with Down syndrome while reducing the
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search